Geary Richard S 4

Accession 0000874015-25-000270

CIK 0000874015other

Filed

Nov 2, 7:00 PM ET

Accepted

Nov 3, 8:14 PM ET

Size

25.2 KB

Accession

0000874015-25-000270

Form 4

Period: 2025-10-31

Senior Vice President

Transactions

Sale
Common Stock
2025-10-31$75.11/sh−34,664$2,603,554→ 79,657 total
Exercise/Conversion
Common Stock
2025-11-03$56.78/sh+775$44,005→ 60,432 total
Exercise/Conversion
Common Stock
2025-11-03$60.89/sh+905$55,105→ 60,562 total
Sale
Common Stock
2025-11-03$75.05/sh−905$67,924→ 59,657 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-10-31−34,585→ 19,876 total
Exercise: $60.89From: 2021-01-02Exp: 2027-01-01→ Common Stock (34,585 underlying)
Sale
Common Stock
2025-10-31$75.11/sh−20,000$1,502,166→ 59,657 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-10-31−34,664→ 16,443 total
Exercise: $56.78From: 2022-01-04Exp: 2028-01-03→ Common Stock (34,664 underlying)
Sale
Common Stock
2025-10-31$75.11/sh−34,585$2,597,621→ 79,657 total
Exercise/Conversion
Common Stock
2025-10-31$56.78/sh+34,664$1,968,222→ 114,321 total
Sale
Common Stock
2025-11-03$75.05/sh−775$58,167→ 59,657 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-03−775→ 15,668 total
Exercise: $56.78From: 2024-01-04Exp: 2028-01-03→ Common Stock (775 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-03−905→ 18,971 total
Exercise: $60.89From: 2023-01-02Exp: 2027-01-01→ Common Stock (905 underlying)
Exercise/Conversion
Common Stock
2025-10-31$60.89/sh+34,585$2,105,881→ 114,242 total

Footnotes (3)

[F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.47 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.25 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

Documents

1 file

IONIS PHARMACEUTICALS INC

CIK 0000874015

Entity typeother